Asunto(s)
Hepatitis B , Inmunoglobulinas , Trasplante de Hígado , Humanos , Trasplante de Hígado/efectos adversos , Hepatitis B/prevención & control , Hepatitis B/inmunología , Inmunoglobulinas/uso terapéutico , Inmunoglobulinas/administración & dosificación , Recurrencia , Virus de la Hepatitis B/inmunología , Virus de la Hepatitis B/efectos de los fármacos , Prevención Secundaria/métodos , Resultado del TratamientoRESUMEN
Porto-sinusoidal vascular disorder (PSVD) encompasses a group of vascular disorders characterized by lesions of the portal venules and sinusoids with clinical manifestations ranging from non-specific abnormalities in serum liver enzymes to clinically overt portal hypertension and related complications. Several reports have documented cases of PSVD in patients with systemic autoimmune conditions, such as systemic lupus erythematosus, systemic sclerosis, and rheumatoid arthritis. It is of note that these diseases share specific pathophysiological features with PSVD, including endothelial dysfunction, vascular inflammation, and molecular signatures. This narrative review aims to summarize the current knowledge on the association between PSVD and systemic autoimmune diseases, emphasizing the importance of promptly recognizing this condition in the rheumatological practice, and highlighting the key aspects where further research is necessary from both pathogenic and clinical perspectives.
Asunto(s)
Enfermedades Autoinmunes , Humanos , Enfermedades Autoinmunes/inmunología , Vena Porta , Hipertensión Portal/inmunología , Hipertensión Portal/fisiopatología , Enfermedades Vasculares/inmunología , Esclerodermia Sistémica/inmunología , Esclerodermia Sistémica/complicacionesRESUMEN
Hepatitis B virus (HBV) reactivation (HBVr) represents a severe and potentially life-threatening condition, and preventive measures are available through blood test screening or prophylactic therapy administration. The assessment of HBVr traditionally considers factors such as HBV profile, including hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen, along with type of medication (chemotherapy; immunomodulants). Nevertheless, consideration of possible patient's underlying tumor and the specific malignancy type (solid or hematologic) plays a crucial role and needs to be assessed for decision-making process.